CRISPR-2 IRX5 F12 Het, IRX5-Het
ITXi002-A-1
General
Cell Line |
|
| hPSCreg name | ITXi002-A-1 |
| Cite as: | ITXi002-A-1 (RRID:CVCL_B5QE) |
| Alternative name(s) |
CRISPR-2 IRX5 F12 Het, IRX5-Het
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
ITXi002-A-2 (CRISPR-2 IRX5 D8 KO, IRX5-KO) ITXi002-A-3 (IRX5-KI, CRISPR-3 IRX5 F6 KI) ITXi002-A (IRX5-Wt, H166Wt C09) |
| Last update | 2nd February 2022 |
| User feedback | |
Provider |
|
| Generator | l’institut du thorax (ITX) |
| Derivation country | France |
External Databases |
|
| BioSamples | SAMEA11025520 |
| Cellosaurus | CVCL_B5QE |
| Wikidata | Q111733528 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
No major chromosomal aberrations were found |
External Databases (Donor) |
|
| BioSamples | SAMEA13166857 |
Ethics
Also have a look at the ethics information for the parental line
ITXi002-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
ITXi002-A.
|
|
Reprogramming method |
|
| Vector type | None |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: StemMACS™ iPS-Brew XF
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| TRA 1-60 |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XY
Karyotyping method:
Molecular karyotyping by SNP array
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
|
Genetic Modification
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.